Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vericel Corp

Get SEC filing alerts via email and in your feed for Vericel Corp

VCEL

Vericel Corp

About Vericel Corp

Vericel Corporation is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care. Its core products include FDA-approved autologous cell therapies MACI and Epicel, and the biologic NexoBrid licensed from MediWound. The company develops innovative biologic and tissue engineering solutions, serving orthopedic and burn treatment markets in the U.S., with a focus on improving patient outcomes and expanding minimally invasive procedures.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vericel Corp

1
1
Vericel Corp Vericel Corporation Reports 30.1% Revenue Growth to $68.4 Million in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Vericel Corp Vericel Corporation Reports 16.5% Revenue Growth to $276.3 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Vericel Corp Vericel Corporation Reports 16.6% Revenue Growth to $67.5 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vericel Corp Vericel Corporation Reports 20.1% Revenue Growth in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vericel Corp Vericel Corporation Reports Q1 2025 Revenue Growth Despite Increased Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vericel Corp Vericel Corporation Reports 20.1% Revenue Growth to $237.2 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Vericel Corp Vericel Corporation Reports 27% Revenue Growth, Improved Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments